Drug Trial Radar · NCT03228667
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Dec 11, 2018
Primary completion
Aug 31, 2029
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 25, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.
Conditions
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Urothelial Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Merkel Cell Carcinoma
- Melanoma
- Renal Cell Carcinoma
- Gastric Cancer
- Cervical Cancer
- Hepatocellular Carcinoma
- Microsatellite Instability
- Mismatch Repair Deficiency
- Colorectal Cancer
Interventions
N-803 + PembrolizumabDrug
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
N-803 + NivolumabDrug
Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
N-803 + AtezolizumabDrug
Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
N-803 + AvelumabDrug
Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
N-803 + DurvalumabDrug
Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.
N-803 + Pembrolizumab + PD-L1 t-haNKDrug
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
N-803 + Nivolumab + PD-L1 t-haNKDrug
Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
N-803 + Atezolizumab + PD-L1 t-haNKDrug
Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
N-803 + Avelumab + PD-L1 t-haNKDrug
Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
N-803 + Durvalumab + PD-L1 t-haNKDrug
Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly
N-803 + Docetaxel + PembrolizumabDrug
The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).
N-803 + Docetaxel + NivolumabDrug
The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.Time frame: Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods
- Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μTime frame: Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Alaska Clinical Research Center
Anchorage, Alaska
Genesis Cancer Center
Hot Springs, Arkansas
Chan Soon-Shiong Institute for Medicine
El Segundo, California
MemorialCare Health System
Fountain Valley, California
Glendale Adventist Medical Center
Glendale, California
University of Southern California Norris Comprehensive Cancer Center
Los Angeles, California
Desert Hematology Oncology Medical Group, Inc.
Rancho Mirage, California
Memorial Healthcare System
Hollywood, Florida
Miami Cancer Institute (Baptist Health South Florida)
Miami, Florida
University of Miami
Miami, Florida
Horizon Oncology Associates
Lafayette, Indiana
University of Iowa Holden Comprehensive Cancer Center
Iowa City, Iowa
Baptist Health - Lexington
Lexington, Kentucky
Baptist Health- Louisville
Louisville, Kentucky
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
University of Minnesota - Masonic Cancer Center
Minneapolis, Minnesota
Mercy Research Joplin
Joplin, Missouri
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center
Springfield, Missouri
Washington University School of Medicine
St Louis, Missouri
St. Vincent Frontier Cancer Center (SCL)
Billings, Montana
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Roswell Park Cancer Institute
Buffalo, New York
University of Rochester
Rochester, New York
Cleveland Clinic - Main Site
Cleveland, Ohio
Mercy Clinic Oklahoma City
Oklahoma City, Oklahoma
Providence Portland Medical Center
Portland, Oregon
Gettysburg/Hanover Cancer Centers
Gettysburg, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
St. Francis Cancer Center/Bon Secours St. Francis Health System
Greenville, South Carolina
Spartanburg Medical Center
Spartanburg, South Carolina
Sanford Clinical Research
Sioux Falls, South Dakota
University of Tennessee Medical Center
Knoxville, Tennessee
Oncology Consultants of Houston
Houston, Texas
Bon Secours Richmond
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.